Evidence map›Paper›PMID 42292522›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Modeling ischemic-type biliary lesion

Zirong Liu, Liuyang Zhu, Pinsheng Han, Wen Tong, Hao Chi, Sen Liu, Yueyue Yang, Libo Wang, Yamin Zhang, Ze Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zirong Liu *Tianjin NanKai Hospital, Tianjin Medical University, Tianjin, China.
Liuyang Zhu *Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Pinsheng Han *Nankai University of Medicine College, Tianjin, China.
Wen TongShandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.
Hao ChiFirst Central Clinical College of Tianjin Medical University, Tianjin, China.
Sen LiuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Yueyue YangCollege of Life Sciences, Nankai University, Tianjin, China.
Libo WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Ze WangState Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, Tianjin, China.
Long YangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Yunfeng CuiTianjin NanKai Hospital, Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ischemic-type biliary lesion (ITBL) remains one of the most common complications following liver transplantation. It is imperative to further explore the occurrence and development mechanism of ITBL. Intrahepatic cholangiocyte organoids (ICOs) derived from human liver tissue replicate the structure and function of bile ducts and serve as an innovative experimental tool for Methods: In this study, ICOs derived from human liver tissue were cultured under ischemia and hypoxia (IH) conditions to establish an Results: IH significantly reduced the diameter and cell viability of ICOs. After exposure to IH for more than 48 h, the proliferation of ICOs decreased, accompanied by increased inflammatory responses and apoptosis. Transcriptomic analysis revealed a landscape of pathophysiological genetic changes in the ITBL model in response to IH. Conclusion: We have presented a novel ITBL model constructed using expandable human ICOs, which is of great significance for exploring the molecular mechanism and potential therapeutic targets of ITBL.

Indexed as

disease modelhypoxia and ischemiaintrahepatic cholangiocyte organoidsischemic-type biliary lesionliver transplantation

Identifiers

PMID42292522
PMCPMC13260613

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.